CYP2C19基因型指导经皮冠脉介入治疗术后抗血小板治疗的有效性及安全性

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (927 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy in patients with coronary artery disease(CAD) after percutaneous coronary intervention(PCI). Methods From April 2013 to February 2015, a total of 718 patients with CAD were admitted and received PCI in the Department of Cardiology, General Hospital of Chinese People’s Armed Police Forces. They were sequentially randomized into study group (n=359) and control group (n=359). In the study group, the CYP2C19 genotypes were detected. The extensive metabolizer (EM) group received clopidogrel 75 mg, qd, the intermediate metabolizer (IM) and poor metabolizer (PM) were randomly assigned to receive either high dose clopidogrel 150 mg, qd or ticagrelor 90mg, bid. The control group routinely received clopidogrel 75 mg, qd. At 6 months, the incidence of major adverse cardiac events (MACE) and bleeding events were observed in the clinical follow up. Results At 6 months follow up, the incidence of MACE in the study group was lower than in the control group (4.7% vs 8.9%,P=0.026). There were no significant difference in the incidence of bleeding events between the two groups(8.1% vs 6.7%,P=0.475). Conclusions In patients with CAD after PCI, CYP2C19 genotype-guided antiplatelet therapy can reduce the incidence of MACE,and does not increase the risk of bleeding event.

Key words： cytochrome 2C19 clopidogrel ticagrelor percutaneous coronary intervention major adverse cardiovascular events

Received: 09 March 2016

ZTFLH:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Lang
	YANG Shengli
	ZHANG Lu
	LIU Ying
	YANG Yong
	and HUANG Jie

Cite this article:

WU Lang,YANG Shengli,ZHANG Lu等. Efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy in patients with coronary artery disease after percutaneous coronary intervention[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(9): 924-927.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2016/V27/I9/924

[1]	Yusuf S, Zhao F, Mehta S R, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med, 2001, 345(23):494-502.
[2]	Bliden K P, Dichiara J, Tantry U S, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? [J]. J Am Coll Cardiol, 2007, 49(6):657-666.
[3]	石红婷,周伯荣,王融.缺血性卒中患者氯吡格雷抵抗的危险因素:前瞻性病例系列研究[J]. 国际脑血管病杂志, 2012, 20(6):423-427.
[4]	孙亚勤,杨胜利,黄洁.CYP2C19基因多态性和氯吡格雷抵抗对冠心病介入术预后的影响[J]. 武警医学, 2015, 26(8):858-862.
[5]	Savi P, Pereillo J M, Uzabiaga M F, et al. Identification and biological activity of the active metabolite of clopidogrel[J]. Thromb Haemost, 2000, 84(5):891-896.
[6]	Hollopeter G, Jantzen H M, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs[J]. Nature, 2001, 409(6817):202-207.
[7]	Uchiyama S. Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment[J]. Cardiovasc Ther, 2011, 29(6):e100-111.
[8]	梁艳,刘振华,白清清. CYP2C19基因型与奥美拉唑治疗消化道溃疡疗效的相关性[J]. 武警医学, 2014, 25(2):142-147.
[9]	Lee J M, Park S, Shin D J, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrelresistance after drug-eluting stent implantation in Koreans[J]. Am J Cardiol,2009,104(1):46-51.
[10]	FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/ Drug Safety/Postmarket Drug Safety Information for Patients and Providers/ucm190836.htm (accessed 3 Aug 2010).
[11]	Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J].Eur Heart J, 2009, 30(8):916-922.
[12]	张卫华, 唐发宽, 林乐健, 等. CYP2C19基因型功能缺失患者介入术后氯吡格雷剂量与心脏不良事件相关性研究[J].中华老年心脑血管病杂志, 2013, 15(10):1041-1043.
[13]	Husted S, Giezen J J. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist[J]. Cardiovasc Ther,2009,27(4):259-274.
[14]	吴丹,杨胜利,路靖,等.冠心病患者支架术后根据检测药物代谢酶CYP2C19基因调整抗血小板治疗的价值[J]. 中国循环杂志, 2015, 30(3):216-219.